Abstract
Aim: Measurable residual disease (MRD) has been recognised as an important prognostic marker in acute lymphoblastic leukaemia (ALL) alongside genetic profiling. Next generation sequencing (NGS) based clonality testing facilitates identification of the full range of clonal populations with underlying DNA sequences, thereby offering improved sensitivity and specificity for MRD monitoring. Here, we interrogate the clinical utility of NGS-based MRD assay for disease monitoring in ALL.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
